Serapha Bio launches with $230 million to develop gene-editing therapy for alpha-1 antitrypsin deficiency
The new gene-editing startup is targeting alpha-1 antitrypsin deficiency, a rare inherited lung and liver disease, following a reverse-merger and a licensing deal with a Chinese biotech company.
A newly formed gene-editing company, Serapha Bio, has publicly launched with $230 million in funding and a licensing agreement with a Chinese biotechnology firm, according to reporting by STAT News. The company emerged from a reverse-merger with a pre-existing biotech entity, a financing structure that allows a private company to gain a public listing without a conventional IPO.
Serapha Bio's lead programme is focused on alpha-1 antitrypsin deficiency (AATD), a rare genetic condition caused by mutations — most commonly the Z allele of the SERPINA1 gene — that impair the folding and secretion of the alpha-1 antitrypsin protein. The condition can cause progressive liver disease and early-onset emphysema, and currently has limited disease-modifying treatment options beyond augmentation therapy and organ transplantation.
The company's gene-editing approach and the precise technology platform have not been fully disclosed in publicly available reporting at the time of writing. The $230 million raise and the scale of the licensing arrangement signal significant investor interest in genetic approaches to AATD at a time when CRISPR-based and base-editing technologies have begun to move into rare-disease clinical development more broadly.
The STAT News article is behind a paywall; this summary is based on the available lede and publicly reported details. Researchers and clinicians with access to the full report may wish to consult the primary source for further detail on the technology platform and development timeline.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
A new company called Serapha Bio has launched with the aim of developing a gene-editing treatment for a rare inherited condition called alpha-1 antitrypsin deficiency (AATD). In AATD, a fault in a gene called SERPINA1 means the body cannot make a working version of a protein that normally protects the lungs and liver. People with AATD can develop lung disease and liver problems.
The company has raised $230 million to fund its research and has signed a deal with another biotech company in China. Gene editing is a technology that researchers are investigating as a way to correct or compensate for faulty genes. This work is at an early stage, and no new treatment has yet been tested in people or approved by regulators.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source STAT News · 2026-06-23Gene-editing startup launches with $230 million and a Chinese licensing deal